Claims for Patent: 6,232,073

Summary for Patent: 6,232,073

Title:	Nucleic acid marker for cancer
Abstract:	The present invention provides using a truncated WT1 gene transcript as a marker for detecting cancer in a subject. The method provides detecting the truncated WT1 gene transcript in a sample from the subject where the truncated gene transcript is characterized by an absence of a 101 base pair segment of intron 5 between nucleic acid positions -101 and -1. Positive detection of the truncated WT1 gene transcript indicates the presence of cancer. The invention provides a truncated WT1 gene transcript characterized by an absence of a 101 base pair segment of intron 5 between nucleic acid positions -101 and -1 and having a length of about two thousand base pairs. The truncated gene transcript is further characterized by containing at their five prime end sequences normally confined to the fifth intron of the WT1 gene, exons six through ten at their three prime end, and an overall length of approximately 2 kb.
Inventor(s):	Ware; Joy L. (Richmond, VA), Dechsukhum; Chavaboon (Richmond, VA), Garrett; Carleton T. (Richmond, VA)
Assignee:	Virginia Commonwealth University (Richmond, VA)
Application Number:	09/434,620
Patent Claims:	1. A method for detecting cancer in a subject, the method comprising: obtaining a sample from the subject; and detecting a truncated WT1 gene transcript in the sample, wherein the truncated WT1 gene transcript comprises RNA complementary to a portion of intron 5 linked to RNA complementary to exons 6-10 and lacks RNA complementary to exons 1-5, and wherein the presence of the truncated WT1 gene transcript indicates the presence of cancer. 2. The method of claim 1 wherein the truncated WT1 gene transcript lacks RNA complementary to a 101 base pair segment of intron 5 between positions -101 and -1. 3. The method of claim 1 wherein the truncated gene transcript includes RNA complementary to SEQ ID NO: 36. 4. The method of claim 1 wherein the detection of the truncated WT1 gene transcript further includes performing reverse transcriptase-polymerase chain reaction using a 5' primer wherein said 5' primer specifically hybridizes to sequences in intron 5 and a 3' primer wherein said 3' primer specifically hybridizes to sequences in exon 6. 5. The method of claim 4 wherein the 5' primer is 5'-GAA CCC TGC ATC TAA AGT GG-3' (SEQ ID NO: 1). 6. The method of claim 4 wherein the detection of the truncated WT1 gene transcript further includes probing cDNA products from the reverse transcriptase-polymerase chain reaction with an oligonucleotide probe wherein the oligonucleotide probe specifically hybridizes to sequences in exon 6. 7. The method of claim 6 wherein detection of the truncated WT1 gene transcript further includes identifying a 95 base pair cDNA product. 8. The method of claim 1 wherein the truncated gene transcript has a length of about two thousand nucleotides. 9. The method of claim 1 wherein positive detection indicates the presence of prostate cancer. 10. The method of claim 1 wherein positive detection indicates the presence of breast cancer. 11. The method of claim 1 wherein positive detection indicates the presence of leukemia. 12. A method for detecting a truncated WT1 gene transcript, the method comprising, obtaining a nucleic acid sample from a subject suitable for performing reverse transcriptase-polymerase chain reaction; performing reverse transcriptase-polymerase chain reaction on the nucleic acid sample using a 5' primer that specifically hybridizes to sequences in intron 5 and a 3' primer that specifically hybridizes to sequences in exon 6, wherein the step of performing generates cDNA fragments which are reverse transcriptase-polymerase chain reaction products; probing the cDNA fragments with a labeled oligonucleotide probe that specifically hybridizes to sequences in exon 6, creating labeled cDNA/probe hybrids; and identifying the labeled cDNA/probe hybrids, wherein identification of the labeled cDNA/probe hybrids is indicative of the presence of the truncated WT1gene transcript in the sample. 13. The method of claim 12 wherein the oligonucleotide probe is 5'-CCA CAG CAC AGG GTA CGA-3' (SEQ ID NO: 2). 14. The method of claim 12 wherein the 5' primer used for performing reverse transcriptase-polymerase chain reaction is 5'-GAA CCC TGC ATC TAA AGT GG-3' (SEQ ID NO: 1). 15. The method of claim 12 wherein the truncated gene transcript includes RNA complementary to SEQ ID NO: 36. 16. The method of claim 12 wherein the cDNA fragments are 95 base pair fragments. 17. The method of claim 1 wherein said portion of intron 5 comprises nucleotides from position -255 to position -102. 18. The method of claim 6 wherein the oligonucleotide probe is 5'-CCA CAG CAC AGG GTA CGA-3' (SEQ ID NO: 2).

Details for Patent 6,232,073

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-02-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-02-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-02-05